PATENT CLAIM ANALYSIS

Application Number: 16339626
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-08
Patent Classification: ["514", "773000"]

Abstract:
A synthetic pulmonary surfactant composition for use in the treatment of inflammatory or cell proliferation disorders of the lungs is provided. The composition comprises a lipidaceous carrier and a peptide complex of poly-L-lysine or a pharmaceutically acceptable salt thereof and poly-L-glutamic acid or poly-L-aspartic acid or a pharmaceutically acceptable salt thereof, the peptide complex having a charge-neutralised region and a positively-charged region. The synthetic pulmonary surfactant composition may be provided in an inhalable formulation. The synthetic pulmonary surfactant composition may also be combined with a drug for use in treating a lung infection, particularly a lung infection characterised by inflammation in the lungs so that the combination provides dual immunomodulatory effects.

Claim (Index 6):
The method as claimed in  claim 1 , wherein the treatment of inflammatory or cell proliferation disorders of the lungs occurs by the inhibition of the secretion of pro-inflammatory cytokines by alveolar macrophages in the presence of the synthetic pulmonary surfactant composition.

Metadata:
- Claim Count in Document: 48.0
- Percentile: 100.0
- Lexical Diversity: 1.82812
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13581442', '11901866', '13992571', '10317787', '11934581']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7765116486795341
- 35 USC 102 Novelty (BERT): 0.5317316711687281
- Combined Prediction Score: 0.7520336509284535
- Mean Citation Score: 247.836276
- Max Citation Score: 352.8875
- Similarity Product: 257.0570713363588

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test